Results 21 to 30 of about 1,753 (162)

Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy [PDF]

Dermatology and Therapy
Introduction A systematic literature review and network meta-analysis (NMA) were conducted to compare the short-term efficacy of lebrikizumab to other biologic and Janus kinase (JAK) inhibitor monotherapies approved for moderate-to-severe atopic ...
Jonathan I. Silverberg, Thomas Bieber, Amy S. Paller, Lisa Beck, Masahiro Kamata, Luis Puig, Marni Wiseman, Khaled Ezzedine, Alan D. Irvine, Peter Foley, James Del Rosso, Linda Stein Gold, Erin Johansson, Martin Dossenbach, Gaia Gallo, Buelent Akmaz, Marta Casillas, Andrei Karlsson, Tristan Curteis, Raj Chovatiya   +19 more
doaj   +4 more sources

A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment Adherence [PDF]

Dermatology and Therapy
Introduction Real-world management of moderate-to-severe atopic dermatitis (AD) may involve treatment interruptions. This indirect comparison evaluated the efficacy of lebrikizumab, dupilumab, and tralokinumab monotherapy in achieving week-52 response at
Jonathan I. Silverberg, Alan D. Irvine, Peter Foley, James Del Rosso, Luis Puig, Linda Stein Gold, Masahiro Kamata, Andreas Wollenberg, H. Chih-ho Hong, Chia-Yu Chu, Yousef Binamer, Martin Dossenbach, Marta Casillas, Gaia Gallo, Buelent Akmaz, Kim Rand, Raj Chovatiya   +16 more
doaj   +2 more sources

Absolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients with Moderate-to-severe Atopic Dermatitis: A Secondary Analysis of Two Phase 3 Trials [PDF]

Acta Dermato-Venereologica
The ADvocate trials (NCT04146363, NCT04178967) investigated adults/adolescents with moderate-to-severe atopic dermatitis (AD) receiving lebrikizumab (LEB) monotherapy, using percent improvement in the Eczema Area and Severity Index (EASI).
Diamant Thaçi, Luis Puig, Sei-ichiro Motegi, Kim Papp, Linda Stein Gold, Leon Kircik, Howard Sofen, Pablo Fernández-Peñas, Pedro Herranz, Christian Vestergaard, Yu-Huei Huang, Martin Dossenbach, Hany Elmaraghy, Gaia Gallo, Maria Jose Rueda, Marta Casillas, Chao Yang, Helena Agell, Meritxell Falqués, Audrey Nosbaum   +19 more
doaj   +2 more sources

Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis [PDF]

Dermatology and Therapy
Introduction Atopic dermatitis (AD) is a chronic skin disease largely driven by interleukin (IL)-13, which is targeted by tralokinumab and lebrikizumab.
Matthias Augustin, April Armstrong, Naiem T. Issa, Anne Sohrt Petersen, Rie von Eyben, Teodora Festini, Tiago Torres   +6 more
doaj   +2 more sources

Lebrikizumab for the Treatment of Moderate to Severe Atopic Eczema: Real-World Experience from a Tertiary Centre [PDF]

Dermatology and Therapy
Introduction Lebrikizumab, a human monoclonal antibody that targets interleukin-13, is approved for treating moderate to severe atopic dermatitis in many regions.
Azmeralda Abraheem, Neenu Sebastian, Firas C. Kreeshan, Tim H. Clayton, Hamish J. A. Hunter, Richard B. Warren   +5 more
doaj   +2 more sources

Short-Term Efficacy of Lebrikizumab Versus Dupilumab in Combination with Topical Corticosteroids in Adults with Moderate-to-Severe Atopic Dermatitis: Matching-Adjusted Indirect Comparison [PDF]

Dermatology and Therapy
Introduction A matching-adjusted indirect comparison evaluated the short-term efficacy of lebrikizumab plus topical corticosteroids (TCS) versus dupilumab plus TCS in adults with moderate-to-severe atopic dermatitis (AD).
Raj Chovatiya, April Armstrong, Leon Kircik, Lluís Puig, Mark G. Kirchhof, Tiago Torres, Yousef Binamer, Gleison Duarte, Bülent Akmaz, Martin Dossenbach, Gaia Gallo, Chao Yang, Lucia Seminario-Vidal, Yuxin Ding, Jonathan I. Silverberg   +14 more
doaj   +2 more sources

Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials

Journal of Dermatological Treatment
Background Lebrikizumab, a high-affinity monoclonal antibody targeting IL-13, previously demonstrated clinical efficacy in three randomized, double-blind, placebo-controlled Phase 3 trials that included adults and adolescents with moderate-to-severe ...
Sherry Chen, Zach Dawson
exaly   +3 more sources

Lebrikizumab Rapidly Lowers Inflammatory Biomarkers with Clinical Correlations in Moderate-to-Severe Atopic Dermatitis [PDF]

Dermatology and Therapy
Introduction Lebrikizumab is a novel monoclonal antibody that selectively binds to interleukin (IL)-13 with high affinity and a slow dissociation rate.
Emma Guttman-Yassky, Zhe Sun, Laura Rebeca Mena, Nathan Hahn, Brian J. Nickoloff, Christoph Preuss, Kimberly Siu, Chitra R. Natalie, Gaia Gallo, Eric Wolf, Kilian Eyerich, Mònica Aparici, Robert J. Benschop, Angela Okragly   +13 more
doaj   +2 more sources

A randomised, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER).

, 2020
BACKGROUND:The anti-interleukin 13 (IL-13) monoclonal antibody lebrikizumab improves lung function in patients with moderate to severe uncontrolled asthma, but its effects on airway inflammation and remodelling are unknown. CLAVIER was designed to assess
Kathryn Mesh (4244278), Julie K Olsson (9382694), J Mark FitzGerald (7950029), Miriam Baca (9382682), Gail M Gauvreau (9382685), Elliot Israel (153177), Lief Bjermer (9382691), Joseph R Arron (8946332), John G Matthews (9382709), David F Choy (8946329), Prescott G Woodruff (8950562), Francis Abreu (9382697), Margaret Solon (4495309), Cary D Austin (9382673), Kaharu Sumino (9382688), Fang Cai (48026), Kit Wong (5849114), Ronald E Ferrando (9382679), Wendy S Putnam (9382703), Peter Bradding (60398), Monica Kraft (362538), Arnaud Bourdin (376853), Monet Howard (9382700), Melissa Gonzalez Edick (9382676), Kun Peng (582722), Cécile TJ Holweg (9382706), CLAVIER Investigators (9382712)   +26 more
core   +7 more sources

Lebrikizumab for atopic dermatitis in the elderly: A case series. [PDF]

JAAD Case Rep
Gruber B.
europepmc   +2 more sources